Biohit Oyj B

BIOBV · Nasdaq Helsinki · Healthcare

2.37EUR −5.6%last day

Price as of 2 October 2026

The price over the past year, with dividends: −18.3%

Performance

1 month

−4.8%

1 year

−18.3%

3 years, per year

+5.3%

5 years, per year

+3.6%

Largest fall, 3 years

−44.2%

Below the peak now

−75.6%

Volatility, 1 year

44.0%

Return with dividends reinvested.

Key figures

P/E

12.2

P/B

2.3

Dividend yield

0.0%

Return on equity

+19.1%

Net margin

+19.3%

Market value

43 m USD

Quality, value and trend

Where Biohit stands against every Nordic stock today. 100 is best.

Quality96

Profitability and a sound balance sheet over time. Better than 96% of Nordic stocks.

Value58

The price measured against earnings, assets and cash flow. Better than 58% of Nordic stocks.

Trend34

The price development over the past year. Better than 34% of Nordic stocks.

Combined73

Quality, value and trend together. Better than 73% of Nordic stocks.

About Biohit

Biohit Oyj B is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 47 employees.

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company offers GastroPanel quick test NT, a rapid and quantitative immunochromatographic test for the detection of Helicobacter pylori and atrophic gastritis; GastroPanel test, a blood test for diagnosis of the function and structure of stomach mucosa; GastroSoft, a software application designed to assist clinicians and general practitioners in interpreting GastroPanel test results; and GP Reader NT for the quantitative determination of various analytes in human samples.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis